Search Results - "Porsteinsson, A. P."

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease by SALLOWAY, S, SPERLING, R, CRANS, G, LIANG, E, QUINN, G, BAIRU, M, PASTRAK, A, CEDARBAUM, J. M, KEREN, R, PORSTEINSSON, A. P, VAN DYCK, C. H, TARIOT, P. N, GILMAN, S, ARNOLD, D, ABUSHAKRA, S, HERNANDEZ, C

“…This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid…”
Get full text

The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia by de Medeiros, Kate, Robert, P, Gauthier, S, Stella, F, Politis, A, Leoutsakos, J, Taragano, F, Kremer, J, Brugnolo, A, Porsteinsson, A P, Geda, Y E, Brodaty, H, Gazdag, G, Cummings, J, Lyketsos, C

“…Neuropsychiatric symptoms (NPS) affect almost all patients with dementia and are a major focus of study and treatment. Accurate assessment of NPS through…”
Get more information

Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021 by Porsteinsson, A. P., Isaacson, R. S., Knox, Sean, Sabbagh, M. N., Rubino, I.

“…Alzheimer’s disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer’s disease progresses along…”
Get full text

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care by Sabbagh, Marwan N., Boada, M., Borson, S., Chilukuri, M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Mild cognitive impairment (MCI) is significantly misdiagnosed in the primary care setting due to multi-dimensional frictions and barriers associated with…”
Get full text

Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting by Sabbagh, Marwan N., Boada, M., Borson, S., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. Moreover, the…”
Get full text

Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies by Sabbagh, Marwan N., Boada, M., Borson, S., Chilukuri, M., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Disease-modifying pharmacotherapies for Alzheimer’s Disease (AD) are currently in late-stage clinical development; once approved, new healthcare…”
Get full text

Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research by Porsteinsson, A P, Clark, E D

Get full text

An open trial of valproate for agitation in geriatric neuropsychiatric disorders by Porsteinsson, A P, Tariot, P N, Erb, R, Gaile, S

“…The authors assessed the efficacy, tolerability and safety of open valproate administration in a group of elderly patients with agitation and neuropsychiatric…”
Get more information

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research by Porsteinsson, A. P., Clark, E. D.

Get full text

Pharmacologic therapy for behavioral symptoms of Alzheimer's disease by Tariot, P N, Ryan, J M, Porsteinsson, A P, Loy, R, Schneider, L S

“…Behavioral signs and symptoms in dementia are common, morbid, classifiable, and treatable. The current state-of-the-art approach is to evaluate carefully for…”
Get more information

Second Generation Anticonvulsant Medications: Their Use in Children by Noviasky, John A., Porsteinsson, Anton P., Lee, Yeong H.

“…The pharmacotherapy of seizure disorders has long relied on a few standard medications such as phenobarbital, phenytoin (Dilantin), valproate (Depakote), and…”
Get full text

Placebo-controlled study of divalproex sodium for agitation in dementia by Porsteinsson, A P, Tariot, P N, Erb, R, Cox, C, Smith, E, Jakimovich, L, Noviasky, J, Kowalski, N, Holt, C J, Irvine, C

“…The authors assessed the efficacy, tolerability, and safety of divalproex sodium for the treatment of agitation associated with dementia in a 6-week,…”
Get more information

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial by Porsteinsson, Anton P, Grossberg, George T, Mintzer, Jacobo, Olin, Jason T

“…To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI)…”
Get more information

Treatment of agitation in dementia by Tariot, Pierre, Gale, Susan E., Castelli, Nancy A., Porsteinsson, Anton P.

“…Agitation, including agressive behaviors, is a common component of dementia. This chapter discusses treatment options for agitation and outlines the efficacy…”
Get full text

Memantine in the treatment of mild-to-moderate Alzheimer's disease by Cosman, Kelly M, Boyle, Lisa L, Porsteinsson, Anton P

“…Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe…”
Get more information

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease' by Rosenberg, Paul B., Onyike, Chiadi U., Katz, Ira R., Porsteinsson, Anton P., Mintzer, Jacobo E., Schneider, Lon S., Rabins, Peter V., Meinert, Curtis L., Martin, Barbara K., Lyketsos, Constantine G.

“…Objectives ‘Depression of Alzheimer's Disease’ (dAD) is a common complication of Alzheimer's disease and is increasingly recognized as a syndrome with a…”
Get full text

Treating Alzheimer's disease: Pharmacologic options now and in the near future by Tariot, Pierre N., Schneider, Lon, Porsteinsson, Anton P.

“…As the field of knowledge about Alzheimer's disease expands, new strategies for treatment are being explored. In the next 5 to 10 years, an explosion in…”
Get full text